Press release from Emotra AB (publ) Kista, 8 April 2022

Emotra AB (publ) releases an updated financial calendar for 2022 and February 2023

Emotra AB ("Emotra" or "the Company") hereby notify the market that they have updated their financial calendar for the coming year.

Future reports

Interim report for January - March 2022

24 May 2022

Interim report for January - June 2022

24 August 2022

Interim report for January - September 2022

28 October 2022

Year-end report for 2022

24 February 2023

The annual general meeting will be held in Stockholm on 21 June 2022. The annual report will be available from the Company's web sitewww.emotra.se no later than three weeks before the annual meeting and can also be ordered from the Company by e-maildaniel.rudeklint@emotra.se.

Emotra has entered an agreement with Mangold Fondkommission concerning a listing of the

Company's shares on Mangold's OTC list. For more information about Mangoldlistan and how it works, please seehttps://mangold.se/mangoldlistan/.Individuals and companies who wish to place trade orders are asked to contact their bank or securities broker.

For further information, please contact:

Daniel Poté, President, telephone: +46 73 234 41 93, E-mail:daniel@emotra.se

__________________________________________________________________________________ Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of neurological research mental health. The Company's methods/products, NeuraMetrix

TC and EDOR®, are unique, proprietary and patent-protected.

EMOTRA AB, Färögatan 33, 164 51 Kista, Sweden

Tel: +46 732-34 41 93,www.emotra.se

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Emotra AB published this content on 11 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 April 2022 08:48:10 UTC.